drugset / Trial / NCT06131580
Canadian Continuation of Roll-over Study in Patients With Endogenous Cushing's Syndrome
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to continue the evaluation of long-term safety of osilodrostat in 7 Canadian patients who have already received osilodrostat treatment in a previous Global Recordati-sponsored roll-over study and who, based on investigators' judgement, will continue benefiting with its administration.
Timeline
- Start
- 2023-10-24
- Primary completion
- 2025-11-24
- Completion
- 2025-11-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | osilodrostat | Small molecule | 1 mg | Oral |
| Subject | osilodrostat | Small molecule | 5 mg | Oral |
| Subject | osilodrostat | Small molecule | 10 mg | Oral |